EICKELMANN, PETER,MARK, MICHAEL,SEMAN, LEO JOHN,THOMAS, LEO,BROEDL, ULI,GREMPLER, ROLF
申请号：
PE0014372011
公开号：
PE00172012A1
申请日:
2010.02.11
申请国别(地区):
PE
年份:
2012
代理人:
摘要：
Refers to a Pharmaceutical composition comprising: a) an inhibitor of sodium Glucose Transporter 2 (sglt2) as canagliflozina Dapagliflozin, atigliflozina remogliflozin, among others (b) an inhibitor of the Enzyme Dipeptidyl peptidase IV (DPPIV) as linagliptin, Sitagliptin Alogliptin, vildagliptin and saxagliptin,Among others and (c) a Third as Antidiabetic Agent metformin, pioglitazone, rosiglitazone, troglitazone, Glibenclamide and metformin, glyburide, among others. The composition is useful for the treatment of Type 2 diabetes mellitus, hyperglycaemia, ObesitySE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DEL TRANSPORTADOR DE SODIO-GLUCOSA 2 (SGLT2) TAL COMO DAPAGLIFLOZINA, CANAGLIFLOZINA, ATIGLIFLOZINA, REMOGLIFLOZINA, ENTRE OTROS B) UN INHIBIDOR DE LA ENZIMA DIPEPTIDIL PEPTIDASA IV (DPPIV) TAL COMO LINAGLIPTINA, SITAGLIPTINA, VILDAGLIPTINA, ALOGLIPTINA, SAXAGLIPTINA, ENTRE OTROS Y C) UN TERCER AGENTE ANTIDIABETICO TAL COMO METFORMINA, PIOGLITAZONA, ROSIGLITAZONA, TROGLITAZONA, GLIBENCLAMIDA, GLIBURIDA, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE DIABETES MELLITUS TIPO 2, HIPERGLUCEMIA, OBESIDAD
